Literature DB >> 8282332

Antihypertensive effect of interleukin-2 in salt-sensitive Dahl rats.

T Ishimitsu1, Y Uehara, A Numabe, H Tsukada, Y Ogawa, S Yagi.   

Abstract

We investigated the effects of interleukin-2, which stimulates the proliferation and maturation of thymus-derived lymphocytes, on hypertension and organ injuries in genetically hypertensive rats. Interleukin-2 (5 x 10(4) U/kg body wt) was subcutaneously injected into Dahl salt-sensitive rats fed a 4% NaCl diet and spontaneously hypertensive rats once a week for 10 weeks. The effects on blood pressure, cardiovascular hypertrophy, and renal function were evaluated. Interleukin-2 treatment lowered blood pressure in Dahl salt-sensitive rats (162 versus 187 mm Hg, P < .005). This antihypertensive effect was associated with an increase in glomerular filtration rate (589 versus 428 mL/d per 100 g body weight, P < .005) and reduction in cardiac weight (268 versus 305 mg/100 g body weight, P < .05). Interleukin-2 also alleviated the marked glomerular sclerosis in Dahl salt-sensitive rats (glomerular injury score, 151 versus 220; P < .001). In contrast, interleukin-2 did not affect the development of hypertension or organ injuries in spontaneously hypertensive rats. Histologically, glomerular and arterial lesions of the kidney were much less marked in spontaneously hypertensive rats than in Dahl salt-sensitive rats. These data indicate that interleukin-2 ameliorates the development of hypertension and cardiac and renal injuries in Dahl salt-sensitive rats.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8282332     DOI: 10.1161/01.hyp.23.1.68

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

Review 1.  Dual opposing roles of adaptive immunity in hypertension.

Authors:  Noureddine Idris-Khodja; Muhammad Oneeb Rehman Mian; Pierre Paradis; Ernesto L Schiffrin
Journal:  Eur Heart J       Date:  2014-03-30       Impact factor: 29.983

2.  Lack of inducible NO synthase reduces oxidative stress and enhances cardiac response to isoproterenol in mice with deoxycorticosterone acetate-salt hypertension.

Authors:  Ying Sun; Oscar A Carretero; Jiang Xu; Nour-Eddine Rhaleb; Fangfei Wang; Chunxia Lin; James J Yang; Patrick J Pagano; Xiao-Ping Yang
Journal:  Hypertension       Date:  2005-11-14       Impact factor: 10.190

3.  Differential involvement of various sources of reactive oxygen species in thyroxin-induced hemodynamic changes and contractile dysfunction of the heart and diaphragm muscles.

Authors:  Mohammad T Elnakish; Eric J Schultz; Rachel L Gearinger; Nancy S Saad; Neha Rastogi; Amany A E Ahmed; Peter J Mohler; Paul M L Janssen
Journal:  Free Radic Biol Med       Date:  2015-03-17       Impact factor: 7.376

Review 4.  Role of the Immune System in Hypertension.

Authors:  Bernardo Rodriguez-Iturbe; Hector Pons; Richard J Johnson
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

5.  ELABELA antagonizes intrarenal renin-angiotensin system to lower blood pressure and protects against renal injury.

Authors:  Chuanming Xu; Fei Wang; Yanting Chen; Shiying Xie; Danielle Sng; Bruno Reversade; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2020-03-16

6.  Mycophenolate mofetil prevents high-fat diet-induced hypertension and renal glomerular injury in Dahl SS rats.

Authors:  Frank T Spradley; Carmen De Miguel; Janet Hobbs; David M Pollock; Jennifer S Pollock
Journal:  Physiol Rep       Date:  2013-11-05

7.  Low Dose of IL-2 Normalizes Hypertension and Mitochondrial Function in the RUPP Rat Model of Placental Ischemia.

Authors:  Evangeline Deer; Lorena M Amaral; Nathan Campbell; Sarah Fitzgerald; Owen Herrock; Tarek Ibrahim; Babbette LaMarca
Journal:  Cells       Date:  2021-10-19       Impact factor: 7.666

Review 8.  Inflammatory Signaling in Hypertension: Regulation of Adrenal Catecholamine Biosynthesis.

Authors:  Collin J Byrne; Sandhya Khurana; Aseem Kumar; T C Tai
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-28       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.